BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave
August 30, 2016 at 08:24 AM EDT
* Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave (naltrexone hcl / bupropion hcl extended release) Source text for Eikon: Further company coverage:
